Rephonic
Artwork for The Lancet Infectious Diseases in conversation with

The Lancet Infectious Diseases in conversation with

The Lancet Group
Antimicrobial Resistance
Clinical Trials
Artificial Intelligence
Public Health
Covid-19
Infectious Diseases
Long COVID
Pediatric Infectious Disease
Sars-Cov-2
Oropuche Virus
Mental Health
Research Funding
Diagnostic Systems
Treatment Strategies
Tuberculosis
Pathogen Characterization
Adaptive Platform Trials
Mpox
Andes Virus
Dengue

The editorial team of The Lancet Infectious Diseases, in conversation with the journal’s authors, explores their latest research and its impact on people’s health, healthcare, and health policy. An audio companion to the journal, this podcast covers a broad range of topics, from mpox diagnostics in Africa, long COVID, adaptive trials in infectious diseases, tuberculosis drug development, and more.... more

PublishesMonthlyEpisodes121Founded5 years ago
Number of ListenersCategories
Health & FitnessMedicine

Listen to this Podcast

Artwork for The Lancet Infectious Diseases in conversation with

Latest Episodes

Fernando Tortosa and Ariel Izcovich discuss various aspects of hantavirus infections with a focus on the situation in Argentina, including transmission, epidemiology, clinical course, management, latest research developments, difficulties in conducti... more

Dr Brecht Ingelbeen and Dr Daniel Valia join Senior Editor Phoebe Hall to discuss a new trial in the journal (the CABU-EICO trial) testing a co-created behavioural intervention bundle to improve antibiotic use, patient management, and water, sanitati... more

Sara Tartof and Matan Yechezkel discuss a new article in The Lancet Infectious Diseases about emerging doxycycline resistance against gonorrhoea and its wider implications for the implementation of doxycycline and the prevention of bacterial sexually... more

Dr Jenny Clarke and Herve Semukunzi discuss a study they and colleagues recently published with us  titled ‘Infection- and vaccine-induced mpox antibodies: validation of a combined mpox IgG ELISA during the clade 1b outbreak in Rwanda’.

They also di... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Infectious Disease Puscast
Infectious Disease PuscastVincent Racaniello
NEJM This Week
NEJM This WeekNEJM Group
This Week in Virology
This Week in VirologyVincent Racaniello
Communicable
CommunicableCMI Communications

Recent Guests

Fernando Tortosa
infectious disease researcher, clinician, and epidemiologist
National University of Rio Negro and Hospital Zonal de Bariloche; McMaster University (clinical guidelines)
Episode: Fernando Tortosa and Ariel Izcovich on hantavirus infections
Ariel Izcovich
infectious disease researcher and clinician
Universidad del Salvador and Hospital Alamán de Buenos Aires
Episode: Fernando Tortosa and Ariel Izcovich on hantavirus infections
Brecht Ingelbeen
From the Institute of Tropical Medicine in Antwerp, Belgium
Institute of Tropical Medicine, Antwerp
Episode: Brecht Ingelbeen and Daniel Valia on a community-based antimicrobial stewardship intervention in Burkina Faso and DRC
Daniel Valia
From the Clinical Research Unit of Nenoro in Burkina Faso
Clinical Research Unit of Nenoro
Episode: Brecht Ingelbeen and Daniel Valia on a community-based antimicrobial stewardship intervention in Burkina Faso and DRC
Matan Yechezkel
A guest on the discussion, affiliated with UC Berkeley
University of California, Berkeley
Episode: Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California
Sara Tartof
A guest on the discussion, affiliated with Kaiser Permanente
Kaiser Permanente
Episode: Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California
Jenny Clarke
Researcher, University of Birmingham
University of Birmingham
Episode: Jenny Clarke and Herve Semukunzi
Herve Semukunzi
Researcher, University of Birmingham and University of Rwanda
University of Birmingham; University of Rwanda
Episode: Jenny Clarke and Herve Semukunzi
Dr. Julia Moore Vogel
Assistant Professor and Senior Programme Director at Scripps Research Translational Research Institute
Scripps Research Translational Research Institute
Episode: Julia Moore Vogel and Danilo Buonsenso on long COVID

Host

Saleha Hassan
Senior Editor for The Lancet Infectious Diseases; contributor to multiple episodes

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Fernando Tortosa and Ariel Izcovich on hantavirus infections
Q: Are there clinical trials for hantavirus infections and why is it difficult to perform them?
There have been small trials with limited power, some halted for futility, and overall challenges stem from geographical spread, rarity, rapid disease progression, and alignment of timely enrollment with treatment windows; despite these hurdles, mortality argues for standardized, multi-center trial efforts.
Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California
Q: What are the implications of your findings for ongoing DOXYPEP rollout and for people taking DOXYPEP?
Findings indicate strong, durable protection for chlamydia and syphilis but waning protection against gonorrhea as Tet-M resistance increases; decisions should be personalized with clinicians, and DOXYPEP should be one part of a broader strategy including testing and safer sex practices.
Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California
Q: What evidence existed prior to your study about DOXYPEP contributing to AMR in Neisseria gonorrhoeae?
Previous randomized trials, especially in France, linked doxycycline exposure to resistance determinants like Tet-M, with US surveillance showing rising Tet-M prevalence; modeling suggested resistance could jeopardize effectiveness over time, motivating real-world evaluation.
Sara Tartof and Matan Yechezkel on durability of doxycycline effectiveness against syphilis, gonorrhoea, and chlamydia after implementation of post-exposure prophylaxis in southern California
Q: Could you explain your study design and the key methodologies that were used?
The study used electronic health record data from Kaiser Permanente Southern California and a test-negative design to estimate DOXYPEP effectiveness, focusing on MSM and transgender women with HIV or on PrEP/PEP, and defined exposure within 90 days prior to testing; regression models adjusted for demographics, STI history, and healthcare utilization, along with linking genomic data on Tet-M resistance.
Jenny Clarke and Herve Semukunzi
Q: What were the aims and design of the study conducted in Rwanda?
The study aimed to perform in-country validation of a serum-based mpox IgG ELISA, compare humoral immunity from natural infection versus vaccination, and assess background seropositivity. It was an observational, multicenter study with three cohorts to evaluate vaccinated, previously infected, and unexposed individuals.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

This program features expert conversations that translate cutting-edge infectious disease research into practical insights for health systems, policy, and patient care. Recent episodes highlight real-world topics such as antimicrobial stewardship and STI prevention with doxycycline-based strategies, serology and outbreak surveillance for mpox, long COVID in both adults and children, adaptive platform trials in infectious diseases, AI's role in diagnostics and public health, and prevention strategies for immunocompromised populations. Across sessions, the emphasis is on how study designs, real-world data, and collaboration shape guidelines, surveillance capabilities, and treatment strategies, while also addressing challenges like antimicrobi... more

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. Infectious Disease Puscast
2. NEJM This Week
3. This Week in Virology
4. JAMA Clinical Reviews
5. Communicable

How many episodes of this podcast are there?

this podcast launched 5 years ago and published 121 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. Fernando Tortosa
2. Ariel Izcovich
3. Brecht Ingelbeen
4. Daniel Valia
5. Matan Yechezkel
6. Sara Tartof
7. Jenny Clarke
8. Herve Semukunzi

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days